Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00578435 · ClinicalTrials.gov registry record · Phase 2

Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target

NCT00578435: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00578435 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00578435, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target

Study Summary

The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.

Interventions

  • PROCEDURE Busulfan, Cyclophosphamide, BMD

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 1994-01
Est. Completion 2008-08
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00578435 record still lists

NCT00578435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 1 intervention - of which Busulfan, Cyclophosphamide, BMD is the first listed.

NCT00578435 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00578435 about?

NCT00578435 is a clinical study titled "Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis". The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.

What is the current status of trial NCT00578435?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1994-01. Estimated completion is 2008-08.

What interventions are being tested in trial NCT00578435?

The interventions under investigation include: Busulfan, Cyclophosphamide, BMD (PROCEDURE).

Who is sponsoring clinical trial NCT00578435?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00578435's enrollment target sits among peer trials

25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00578435, the US trial registry maintained by the National Library of Medicine. NCT00578435 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.